Serum-free light chains as a dependable biomarker for stratifying patients with metabolic dysfunction-associated steatotic liver disease.
FIB‐4
MASLD
adaptative immunity
fibrosis
free light chain
liver function test
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
17 Jul 2024
17 Jul 2024
Historique:
revised:
29
05
2024
received:
04
11
2023
accepted:
23
06
2024
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
17
7
2024
Statut:
aheadofprint
Résumé
Adaptive immunity is gaining a significant role in progression of metabolic dysfunction-associated steatotic liver disease (MASLD). B-cell activity can be assessed by serum-free light chains (sFLCs) k and λ levels. The objective of the present investigation is to examine the utility of sFLCs as non-invasive biomarkers for the stratification of MASLD. We enrolled a consecutive cohort from an outpatient liver unit. Diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) was made with liver biopsy according to current guidelines. Compensated advanced chronic liver disease (cACLD) and clinically significant portal hypertension (CSPH) were defined according to Baveno VII criteria. sFLCs were measured by turbidimetry using an immunoassay. We evaluated 254 patients, 162/254 (63.8%) were male. Median age was 54 years old, and the median body mass index was 28.4 kg/m sFLCs could be a simple biomarker for stratification of cACLD in MASLD patients.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Adaptive immunity is gaining a significant role in progression of metabolic dysfunction-associated steatotic liver disease (MASLD). B-cell activity can be assessed by serum-free light chains (sFLCs) k and λ levels. The objective of the present investigation is to examine the utility of sFLCs as non-invasive biomarkers for the stratification of MASLD.
METHODS
METHODS
We enrolled a consecutive cohort from an outpatient liver unit. Diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) was made with liver biopsy according to current guidelines. Compensated advanced chronic liver disease (cACLD) and clinically significant portal hypertension (CSPH) were defined according to Baveno VII criteria. sFLCs were measured by turbidimetry using an immunoassay.
RESULTS
RESULTS
We evaluated 254 patients, 162/254 (63.8%) were male. Median age was 54 years old, and the median body mass index was 28.4 kg/m
CONCLUSION
CONCLUSIONS
sFLCs could be a simple biomarker for stratification of cACLD in MASLD patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Maria Elena Ainora
(ME)
Sebastiano Archilei
(S)
Luigi Andrea Antuofermo
(LA)
Marco Biolato
(M)
Riccardo Beschi
(R)
Nicoletta De Matthaeis
(N)
Matteo Garcovich
(M)
Roberta Iaccarino
(R)
Eleonora Maggio
(E)
Giuseppe Marrone
(G)
Lucrezia Petrucci
(L)
Fabrizio Pizzolante
(F)
Laura Riccardi
(L)
Fabrizio Termite
(F)
Simone Varca
(S)
Nicholas Viceconti
(N)
Fabio Maria Vecchio
(FM)
Maria Assunta Zocco
(MA)
Informations de copyright
© 2024 The Author(s). Liver International published by John Wiley & Sons Ltd.
Références
Rinella ME, Lazarus JV, Ratziu V, et al. A multi‐society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542‐1556. doi:10.1016/j.jhep.2023.06.003
Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11‐20.
Younossi ZM, Paik JM, Henry L, et al. The growing economic and clinical burden of nonalcoholic Steatohepatitis (NASH) in the United States. J Clin Exp Hepatol. 2023;13:454‐467.
Le P, Payne JY, Zhang L, et al. Disease state transition probabilities across the Spectrum of NAFLD: a systematic review and meta‐analysis of paired biopsy or imaging studies. Clin Gastroenterol Hepatol. 2023;21:1154‐1168.
Chhatwal J, Dalgic OO, Chen W, et al. Analysis of a simulation model to estimate long‐term outcomes in patients with nonalcoholic fatty liver disease. JAMA Netw Open. 2022;5:e2230426.
Sutti S, Albano E. Adaptive immunity: an emerging player in the progression of NAFLD. Nat Rev Gastroenterol Hepatol. 2019;17(2):81‐92. doi:10.1038/s41575-019-0210-2
Barrow F, Khan S, Wang H, Revelo XS. The emerging role of B cells in the pathogenesis of NAFLD. Hepatol Baltim Md. 2021;74:2277‐2286.
Thapa M, Chinnadurai R, Velazquez VM, et al. Liver fibrosis occurs through dysregulation of MyD88‐dependent innate B‐cell activity. Hepatol Baltim Md. 2015;61:2067‐2079.
Lund FE. Cytokine‐producing B lymphocytes‐key regulators of immunity. Curr Opin Immunol. 2008;20:332‐338.
Barrow F, Khan S, Fredrickson G, et al. Microbiota‐driven activation of intrahepatic B cells aggravates NASH through innate and adaptive Signaling. Hepatol Baltim Md. 2021;74:704‐722.
Napodano C, Pocino K, Gulli F, et al. Mono/polyclonal free light chains as challenging biomarkers for immunological abnormalities. Adv Clin Chem. 2022;108:155‐209.
Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS‐related lymphoma. J Clin Oncol. 2010;28:773‐779.
Aggarwal R, Sequeira W, Kokebie R, et al. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Arthritis Care Res. 2011;63:891‐898.
Pottel H, Björk J, Rule AD, et al. Cystatin C‐based equation to estimate GFR without the inclusion of race and sex. N Engl J Med. 2023;388:333‐343.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313‐1321.
de Franchis R, Bosch J, Garcia‐Tsao G, Reiberger T, Ripoll C, Baveno VII Faculty. Baveno VII—renewing consensus in portal hypertension. J Hepatol. 2022;76:959‐974.
Cigliana G, Gulli F, Napodano C, et al. Serum free light chain quantitative assays: dilemma of a biomarker. J Clin Lab Anal. 2018;32:e22243.
Matsumori A, Shimada T, Nakatani E, et al. Immunoglobulin free light chains as an inflammatory biomarker of heart failure with myocarditis. Clin Immunol Orlando Fla. 2020;217:108455.
Bramlage CP, Froelich B, Wallbach M, et al. The significance and predictive value of free light chains in the urine of patients with chronic inflammatory rheumatic disease. Clin Rheumatol. 2016;35:2939‐2946.
Gulli F, Napodano C, Marino M, et al. Serum immunoglobulin free light chain levels in systemic autoimmune rheumatic diseases. Clin Exp Immunol. 2020;199:163‐171.
Hutchison CA, Burmeister A, Harding SJ, et al. Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney disease. Mayo Clin Proc. 2014;89:615‐622.
Basile U, Gulli F, Gragnani L, et al. Free light chains: eclectic multipurpose biomarker. J Immunol Methods. 2017;451:11‐19.
Bruzzì S, Sutti S, Giudici G, et al. B2‐lymphocyte responses to oxidative stress‐derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD). Free Radic Biol Med. 2018;124:249‐259.
Kanemitsu‐Okada K, Abe M, Nakamura Y, et al. Role of B cell‐activating factor in fibrosis progression in a murine model of non‐alcoholic Steatohepatitis. Int J Mol Sci. 2023;24:2509.
Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwälder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease ‐ novel insights into cellular communication circuits. J Hepatol. 2022;77:1136‐1160.
Wiering L, Tacke F. Treating inflammation to combat non‐alcoholic fatty liver disease. J Endocrinol. 2023;256:e220194.
Rensen SS, Slaats Y, Nijhuis J, et al. Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am J Pathol. 2009;175:1473‐1482.
Ma J, Jiang D, Gong X, et al. Free immunoglobulin light chain (FLC) promotes murine colitis and colitis‐associated colon carcinogenesis by activating the inflammasome. Sci Rep. 2017;7:5165.
Arelaki S, Koletsa T, Sinakos E, et al. Neutrophil extracellular traps enriched with IL‐1β and IL‐17A participate in the hepatic inflammatory process of patients with non‐alcoholic steatohepatitis. Virchows Arch Int J Pathol. 2022;481:455‐465.
Wang H, Zhang H, Wang Y, et al. Regulatory T‐cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non‐alcoholic steatohepatitis. J Hepatol. 2021;75:1271‐1283.
Du J, Zhang J, Chen X, et al. Neutrophil extracellular traps induced by pro‐inflammatory cytokines enhance procoagulant activity in NASH patients. Clin Res Hepatol Gastroenterol. 2022;46:101697.
Dömer D, Walther T, Möller S, Behnen M, Laskay T. Neutrophil extracellular traps activate Proinflammatory functions of human neutrophils. Front Immunol. 2021;12:636954.
Melbouci D, Haidar Ahmad A, Decker P. Neutrophil extracellular traps (NET): not only antimicrobial but also modulators of innate and adaptive immunities in inflammatory autoimmune diseases. RMD Open. 2023;9:e003104.
Jeremic I, Djuric O, Nikolic M, et al. Neutrophil extracellular traps‐associated markers are elevated in patients with systemic lupus erythematosus. Rheumatol Int. 2019;39:1849‐1857.
Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatol Baltim Md. 2009;49:1877‐1887.
Reid DT, Reyes JL, McDonald BA, Vo T, Reimer RA, Eksteen B. Kupffer cells undergo fundamental changes during the development of experimental NASH and are critical in initiating liver damage and inflammation. PLoS One. 2016;11:e0159524.
Kotsiliti E, Leone V, Schuehle S, et al. Intestinal B cells license metabolic T‐cell activation in NASH microbiota/antigen‐independently and contribute to fibrosis by IgA‐FcR signalling. J Hepatol. 2023;79:296‐313.
McPherson S, Henderson E, Burt AD, Day CP, Anstee QM. Serum immunoglobulin levels predict fibrosis in patients with non‐alcoholic fatty liver disease. J Hepatol. 2014;60:1055‐1062.
D'Amico G, Garcia‐Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217‐231.
Ripoll C, Groszmann R, Garcia‐Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481‐488.
Moreau R, Jalan R, Gines P, et al. Acute‐on‐chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426‐1437.
Arroyo V, Angeli P, Moreau R, et al. The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol. 2021;74:670‐685.
Jalan R, D'Amico G, Trebicka J, Moreau R, Angeli P, Arroyo V. New clinical and pathophysiological perspectives defining the trajectory of cirrhosis. J Hepatol. 2021;75:S14‐S26.
Gracia‐Sancho J, Russo L, García‐Calderó H, García‐Pagán JC, García‐Cardeña G, Bosch J. Endothelial expression of transcription factor Kruppel‐like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. Gut. 2011;60:517‐524.
Friedman SL, Pinzani M. Hepatic fibrosis 2022: unmet needs and a blueprint for the future. Hepatol Baltim Md. 2022;75:473‐488.
Engelmann C, Clària J, Szabo G, Bosch J, Bernardi M. Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol. 2021;75(Suppl 1):S49‐S66.